Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
          • Financials
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • What is a Clinical Trial?
          • Your Involvement Matters
          • Current Trials & Studies
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • World FSHD Day
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Current Trials and Studies
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • For Industry
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Voice of the Patient Report
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • Search
  • Financials
  • Patient Library
  • Blog
  • Calendar
  • JOIN US
  • Donate
  • JOIN US
  • Donate

Avidity receives IND clearance for FSHD therapeutic

Home / General / Avidity receives IND clearance for FSHD therapeutic

Posted on: Sep 27, 2022

AOC1020 will be the first RNA therapy to be tried in FSHD

Avidity Biosciences announced today that it had received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for AOC 1020, its experimental therapy for facioscapulohumeral muscular dystrophy. This means the San Diego-based biopharmaceutical company is allowed to begin testing AOC 1020 in human clinical trials. Avidity said it had also received IND clearance for another program, AOC 1044, for Duchenne muscular dystrophy mutations amenable to exon 44 skipping.

This welcome news was included in a press release that also announced that the FDA has placed a “partial clinical hold” on new participant enrollment in Avidity’s Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Close to 40 participants are currently enrolled in the MARINA and MARINA open label extension (MARINA-OLE™) trials. All participants, whether they are on AOC 1001 or placebo, may continue in their current dosing cohort although no additional participants may be enrolled until the partial clinical hold is resolved.

“The partial clinical hold is in response to a serious adverse event reported in a single participant in the 4mg/kg cohort of the MARINA study,” the company’s press release explained. “The safety of participants enrolled in clinical studies is Avidity’s first priority. Avidity is working closely with the FDA and the trial investigator to assess the cause of this event. The company is taking all necessary steps to resolve the partial clinical hold on new participant enrollment as quickly as possible.”

According to the FDA, a “serious adverse event” is any “undesirable experience associated with the use of a medical product in a patient,” which can include death, life-threatening complications, hospitalization, disability or permanent damage. The adverse event may or may not be due to the experimental drug, and when such an event occurs, the drug developer must pause the trial until it can determine the cause. If the adverse event is shown to not pose a risk to other patients, the trial may be allowed to proceed.

Avidity’s experimental treatments are a new type of RNA therapy based on Antibody Oligonucleotide Conjugates (AOCs™). Their approach uses antibodies that recognize and bind to proteins on the surface of muscles in order to delivery therapeutic RNA molecules into the muscle. For their FSHD therapy, Avidity’s AOC 1020 delivers a molecule that prevents the DUX4 gene from producing the toxic DUX4 protein. (See Dr. Jeff Statland’s talk about AOC-based FSHD therapies.)

The company has tested its drugs extensively in animals to minimize safety risks, but any drug, especially one that has never been tried in humans before, can cause side effects. This is why human clinical trials often start with small, homogenous groups of participants before proceeding into larger groups of patients in order to prioritize participant safety.

We will be keeping a close eye on the status of the MARINA study as well as the progress of AOC 1020 into FSHD clinical trials. Sign up for our e-alerts to stay informed.

Read the full Avidity press release here.

Share

Filed Under: FSHD Research, General

Comments

  1. Sylvie says

    September 28, 2022 at 1:12 am

    What a good news 🙂

    Reply
  2. Vaghela rajendra R says

    September 29, 2022 at 6:11 am

    Can the people of India also participate in this?

    Reply
    • jkinoshita says

      October 3, 2022 at 4:03 pm

      We expect that clinical trial enrollment will be limited to patients who are citizens or legal residents in locations close to the clinical trial sites. We have not seen the locations yet, but we expect they will mostly be in the U.S., Canada, EU, and UK.

      Reply
  3. Maegann Chatham says

    September 29, 2022 at 10:40 am

    I have FSHD and was diagnosed at 16. My daughter and mother, as well as many other family members have it as well. Where can we get this?

    Reply
    • jkinoshita says

      October 3, 2022 at 12:01 pm

      Just to be clear, the next step for Avidity is to test whether their drug is safe and effective through an experiment in patients, which is called a clinical trial. Avidity has not yet announced where and when the trial will begin. To get the latest updates from us, be sure to sign up here: https://go.fshdsociety.org/join-the-community

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

FSHD Society
P.O. Box 411617
Boston, MA 02241-1617

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by